Aclaris Therapeutics (ACRS) versus Arcturus Therapeutics (ARCT) Head to Head Comparison

Aclaris Therapeutics (NASDAQ: ACRS) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Insider & Institutional Ownership

92.0% of Aclaris Therapeutics shares are owned by institutional investors. 16.3% of Aclaris Therapeutics shares are owned by company insiders. Comparatively, 0.0% of Arcturus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Aclaris Therapeutics and Arcturus Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aclaris Therapeutics N/A N/A -$48.07 million ($2.16) -11.40
Arcturus Therapeutics N/A N/A -$24.60 million ($5.32) -1.78

Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Aclaris Therapeutics and Arcturus Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aclaris Therapeutics 0 0 4 0 3.00
Arcturus Therapeutics 0 6 2 0 2.25

Aclaris Therapeutics currently has a consensus target price of $41.25, suggesting a potential upside of 67.48%. Arcturus Therapeutics has a consensus target price of $1.54, suggesting a potential downside of 83.72%. Given Aclaris Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Aclaris Therapeutics is more favorable than Arcturus Therapeutics.


This table compares Aclaris Therapeutics and Arcturus Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aclaris Therapeutics N/A -30.76% -29.25%
Arcturus Therapeutics N/A -36.83% -34.70%

Volatility and Risk

Aclaris Therapeutics has a beta of 1.96, indicating that its share price is 96% more volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500.


Aclaris Therapeutics beats Arcturus Therapeutics on 9 of the 11 factors compared between the two stocks.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc. is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer. The Company’s drug discovery platform KINect technology is a kinase-focused drug discovery engine utilizing computational chemistry to integrate proprietary compound collections and highly experienced biologists and medicinal chemists to identify and advance potential candidates into preclinical and clinical development.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Ltd, formerly Alcobra Ltd, is an Israel-based preclinical-stage biopharmaceutical company primarily focused on the discovery, development and commercialization of ribonucleic acid (RNA) medicines using lipid-mediated nanoparticle delivery system (LUNAR) and Unlocked Nucleomonomer Agent (UNA) Oligomer chemistry technology platforms. The Company, through Arcturus Therapeutics Inc, its wholly owned subsidiary based in the United States, is focused on developing RNA medicines for rare, infectious, fibrotic and respiratory diseases with unmet medical needs, including cystic fibrosis, nonalcoholic steatohepatitis (NASH) and rare liver diseases, as well as replicon RNA vaccines.

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply